Brittany de Temple
About
In The Last Decade
Brittany de Temple
8 papers receiving 529 citations
Hit Papers
Peers
Comparison fields: 5 of 38
- Epidemiology 408
- Molecular Biology 213
- Endocrinology, Diabetes and Metabolism 208
- Hepatology 119
- Cell Biology 59
Countries citing papers authored by Brittany de Temple
This map shows the geographic impact of Brittany de Temple's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brittany de Temple with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brittany de Temple more than expected).
Fields of papers citing papers by Brittany de Temple
This network shows the impact of papers produced by Brittany de Temple. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brittany de Temple. The network helps show where Brittany de Temple may publish in the future.
Co-authorship network of co-authors of Brittany de Temple
This figure shows the co-authorship network connecting the top 25 collaborators of Brittany de Temple. A scholar is included among the top collaborators of Brittany de Temple based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brittany de Temple. Brittany de Temple is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 5 | |
| 2 | 0 | |
| 3 | Efruxifermin in Compensated Liver Cirrhosis Caused by MASH breakdown → | 19 |
| 4 | 1 | |
| 5 | 37 | |
| 6 | 6 | |
| 7 | Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial breakdown → | 146 |
| 8 | 72 | |
| 9 | 0 | |
| 10 | Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial breakdown → | 255 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.